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ABSTRACT
We aimed to assess the efficacy of external beam radiotherapy (EBRT) in central airway obstruction (CAO) and associated factors for 
metastatic lung cancer (MLC) patients. Records of 72 MLC patients presenting with CAO were retrospectively analyzed. The serial 
chests X-rays prior and after the EBRT were compared for response assessment. The primary end-point was radiologic response, 
while overall- (OS) and CAO-free survival, and predictors of better outcomes constituted secondary endpoints. The EBRT doses 
ranged between 8 to 40 Gy (1-13 fractions). Median follow-up and OS were 5.6 (range: 1.3-17.8) and 7.6 months (95% CI: 6.5-8.7), 
respectively. Objective CAO resolution was achieved in 58 patients (80.6%) on serial chest X-rays with a median time to maximum 
CAO response of 23 days (range: 3-86). In responders the response was durable (8.1 months) almost nearly for all their remaining life 
spans (8.3 months) with only 19.0% CAO recurrences. Median OS was also significantly longer in responders (8.3 vs. 2.4 months; p< 
0.001). Small-cell histology (p= 0.002), tumor size <5.3 cm (p= 0.007), and biologically equivalent dose (BED10) ≥39 Gy (p< 0.001) 
were associated with better CAO response, while the presence of CAO response (p< 0.001) and BED10 ≥39 Gy (p= 0.008) were 
the factors to relate with better OS on multivariate analyses. The EBRT proves effective and durable CAO palliation with only 19.0% 
re-CAO rate in MLC patients. Better CAO responses may be achieved in patients treated with smaller tumor size, small-cell histology, 
and higher BED10 values.   
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ÖZET
Akciğer Kanseri İlişkili Santral Hava Yolu Tıkanıklığı: Radyoterapiden Kim Daha Fazla Fayda Görür?
Metastatik akciğer kanserine (MAK) bağlı gelişen santral hava yolu tıkanıklığının (SHT) palyatif tedavisinde radyoterapinin (RT) 
etkinliği ve etkinlikle ilişkili faktörlerin araştırılması amaçlanmıştır. Bu amaçla 72 hasta geriye dönük olarak incelenmiştir. RT’ye cevap 
değerlendirmesi seri akciğer grafileri (SAG) kullanılarak yapılmıştır. Primer sonlanım noktası radyolojik cevap; ikincil sonlanım noktaları 
genel sağ kalım (GS), SHT’siz sağ kalım ve daha iyi sonuç göstergelerinin araştırılması olarak belirlenmiştir. RT dozları 8-40 Gy’dir (1-13 
fraksiyon). Ortanca takip süresi ve GS sırasıyla 5.6 (aralık: 1.3-17.8) ve 7.6 (95% CI: 6.5-8.7) aydır. SAG ile takipte 58 (%80.6) hastada 
objektif yanıt elde edilmiş olup SHT’deki maksimum düzelme ortanca 23 günde (3-86) gerçekleşmiştir. RT’ye yanıt veren hastalardaki 
ortanca 8.3 aylık GS süresinin 8.1 ayında amaçlanan palyasyon sağlanırken; hastaların %19’da SHT tekrarlamıştır. Ortanca GS süresi 
RT’ye yanıt veren (8.3 karşın 2,4 ay; p< 0.001) hastalarda daha yüksek bulunmuştur. Küçük hücreli histoloji (p= 0.002), tümör boyutu-
nun <5.3 cm (p= 0.007) ve biyolojik eşdeğer dozun ≥39 Gy (p< 0.001) olması RT sonrası SHT’de daha iyi yanıtla ilişkili bulunurken; çok 
değişkenli analizlerde RT’ye yanıt (p< 0.001)  ve BED10 ≥39 Gy (p= 0.008) daha uzun GS ile ilişkili bulunmuştur. RT ile MAK’da gelişen 
SHT’de etkin ve uzun süreli palyasyon sağlanmıştır (sadece %19’luk SHT’de tekrarlama). Tümör boyutu küçük olan, küçük hücreli alt 
histolojiye sahip ve yüksek doz RT uygulanan (BED10) hastalarda SHT’de daha iyi sonuçlar elde edilebilir.
Anahtar Kelimeler: Santral hava yolu tıkanıklığı, Metastatik akciğer kanseri, Eksternal beam radyoterapi   
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INTRODUCTION
Central airway obstruction (CAO), defined as ob-
struction of the lumen or air flow at the level of tra-
chea, main carina and main bronchi due to intra- or 
extraluminal disease is one of the major complica-
tions of locally advanced- and metastatic lung can-
cer (MLC) which deteriorates patients’ quality of 
life (QoL) measures and survival outcomes. CAO 
may develop in nearly up to 30% lung cancer pa-
tients either at the early phases or later anywhere 
during the disease course.1,2                 
Although the well-established initial management 
of MLC constitutes systemic chemotherapy, yet 
persistent symptoms related with CAO may man-
date the urgent use of invasive or/and non-invasive 
interventions against primary obstructive area as 
the initial step of treatment.3,4 In these situations, 
the commonly utilized treatment modalities in-
volve the stent placement, dilatation, endoscopic 
laser ablation (ELA), argon plasma coagulation 
(APC), photodynamic therapy (PDT), endobron-
chial brachytherapy (EBB) and external beam ra-
diotherapy (EBRT).5-7 In general, ELA, APC, PDT, 
and EBB are implemented for the treatment of in-
traluminal tumors, while stent placement is usually 
reserved mainly for the obstructions caused by ex-
traluminal masses with/without intraluminal exten-
sions.8 Aside the technical difficulties in their use, 
almost each of these modalities has the potential 
to cause severe complications; such as, fatal hem-
orrhage and lower respiratory tract infections for 
airway stents9-12 or tracheobronchitis, hemoptysis, 
tracheomalacia and bronchial stenosis for EBB8, 
which frequently precluding their use as the first 
maneuver for CAO palliation. These severe com-
plications may underlie the obvious need for alter-
native noninvasive but efficient treatment modali-
ties with minimal toxicity profiles. 
Considering its well-recognized tumor downsizing 
and palliative efficacy irrespective of the tumor’s 
relation with bronchial lumen, together with its 
noninvasive characteristic and minimal toxicity 
profile EBRT appears to be a suitable candidate 
for CAO palliation.8 Therefore, in scarcity of such 
studies, we planned to retrospectively assess the 
efficacy of palliative EBRT and associated prog-
nostic factors in MLC patients presenting with 
clinical symptoms or chest X-ray findings of CAO.
PATIENTS and METHODS
Eligibility Criteria
A retrospective database search was performed 
to identify MLC patients presenting with clinical 
symptoms or chest X-ray findings of CAO. To be 
eligible, patients had to meet the following crite-
ria: histologically proven non-small cell- (NSCLC) 
or small-cell lung carcinoma (SCLC) diagnosis; 
age >18; Eastern Cooperative Oncology Group 
(ECOG) performance of 0-3; available pre- and 
post-EBRT chest X-rays, available EBRT dosimet-
ric datasets, and no history of prior thoracic radio-
therapy (RT) to the apparent CAO port. The study 
protocol was approved by the institutional review 
board before any data collection.
Radiotherapy
Patients underwent volumetric treatment planning 
computerized tomography (CT) scan using wing 
board in the treatment position. The gross tumor 
volume (GTV) solely included the apparent mass 
on computerized tomography which was judged to 
cause CAO. The available 18F-flourodeoxyglucose 
(FDG)-positron emission tomography was utilized 
in cases with accompanying atelectasis in order to 
discriminate from the tumor. According to our in-
stitutional standards for such patients the clinical 
target volume (CTV) was equivalent to GTV, while 
the planning target volume (PTV) was created by 
adding an isometric 1 cm margin to the CTV at all 
directions. The right, left and total lungs, heart, spi-
nal cord (SC), esophagus and whole liver were all 
delineated as the organs at risk (OAR). Total doses 
of 8 to 40 Gy in 1 to 13 fractions were prescribed 
and 3-dimensional conformal EBRT technique was 
utilized in all patients. The optimal EBRT schedule 
was chosen by taking into account the performance 
status of patient, tumor size and proximity with 
the OAR. To be acceptable, the 95% isodose line 
had to cover the 100% of the PTV and maximal 
PTV dose was restricted to 107% of the prescribed 
dose. In case of using the 39-40 Gy schedules in 13 
and 10 fractions, respectively, the maximum dose 
constraint of spinal cord was calculated utilizing 
the biologically equivalent dose-2 Gy (BED2= 
n.d.(1+d/α/ß), with 36.6 Gy and 30.6 Gy maximum 
point doses being set for 39 and 40 Gy,  respective-
ly. Concurrent chemotherapy was not permitted.
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Response Assessment
The obstructive symptoms and treatment related 
acute toxicity were assessed every week or more 
frequently when necessary during the treatment. 
Revealed from the cohorts any symptom scoring 
systems or patient-reported questionnaires were 
not utilized. Therefore, the symptomatic response 
was assessed subjectively and solely by depending 
on the patients’ verbal response at each meeting 
with the best verbal response being the best symp-
tomatic response date. After the treatment, patients 
were first monitored at monthly intervals for the 
first 3 months and at 3-month intervals or more 
frequently thereafter. The objective response was 
assessed by comparison of the chest X-rays which 
were obtained prior and following the treatment.
Statistical Analysis
The primary end-point of the present study was the 
radiologic CAO response rate to EBRT. The sec-
ondary end-points were survival outcomes, name-
ly overall survival and median CAO-free survival 
which were defined as the interval between the first 
EBRT day and the date of death/last visit and the 
date of lung re-obstruction, respectively. Survival 
was analyzed by using the Kaplan-Meier method. 
In order to determine the potential impact of con-
tinuous variables on survival and CAO response 
rates, Receiver Operating Curve (ROC) was uti-
lized to categorize patients into groups according 
to the defined cut-off values, if available. The sur-
vival curves of subgroups were compared by using 
two-sided log-rank tests. A cox proportional hazard 
model was utilized for analyzing the relationship 
between different variables and survival. All tests 
were two-tailed. A p-value ≤ 0.05 was considered 
significant. For the assessment of the potential 
correlation between CAO response to EBRT and 
available covariates, the Spearman Analysis was 
utilized with related P (rho) values. All the deliv-
ered doses were converted to BED10 to perform 
more reliable comparison and analysis between the 
treatment schedules. 
RESULTS
A total of 72 MLC patients with CAO were identi-
fied to be treated with palliative EBRT at our in-
stitution and included in this retrospective cohort 
analysis. Patient and treatment characteristics 
were as summarized in Table 1. Median age was 
64 years (range: 46-79) with 72% being male and 
75% having ECOG 0-2. Median EBRT dose was 
30 Gy (range: 8-40) which was administered in 10 
fractions (range: 1-13).Treatment was relatively 
well tolerated with only 5 (6.9%) acute grade 3 
toxicities (4 pneumonitis and 1 esophagitis) and no 
report of late grade 3-5 toxicity. 
Although 11 (19.0%) later developed re-CAO at 
somewhere during the follow-up period, resolution 
of CAO to some degree was reported in 58 patients 
(80.6%) on serial chest X-ray examinations either 
during or after the completion of EBRT with no no-
table response in remaining 14 (19.6%). The me-
dian time to achievable maximum expansion of the 
obstructed lung was 23 days (range: 3-86) from the 
initiation date of EBRT for the responders which 
remained durable for a median of 8.1 months (95% 
CI: 3.7-12.5). Time to maximum CAO response 
Table 1. Patient baseline and treatment characteristics 
Characteristics All patients 
Median age, years (range) 64 (46-79)
Gender (N;%)
  Male 52 (72.0)
  Female 20 (28.0)
ECOG performance (N;%)
  1 36 (50.0)
  2 18 (25.0)
  3 18 (25.0)
Histology (N;%) 
  NSCLC 53 (73.6.0)
  SCLC 19 (26.4.0)
EBRT schedule (N;%) 
  1 x 8 Gy 7 (9.8)
  5 x 4 Gy 13 (18.0)
  10 x 3 Gy 30 (41.7)
  12 x 3 Gy 5 (7.0)
  13 x 3 Gy 13 (18.0)
  10 x 4 Gy 4 (5.5)
ECOG, eastern cooperative oncology group; NSCLC, non-
small cell lung carcinoma; SCLC, small-cell lung carcinoma; 
EBRT, external beam radiotherapy; Gy, gray
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was significantly shorter in the SCLC than the 
NSCLC cohort (5 vs. 28 days; p= 0.02). Similarly, 
maximum CAO response rate was also significant-
ly higher in SCLC patients (89.5% vs. 77.3%; p= 
0.02).
At a median follow-up of 5.6 months (range 1.3-
17.8), the median OS and CAO free survival were 
7.6 (95% CI:  6.5-8.7) and 7.2 months (95% CI: 
6.0-8.5) for the entire study population, respec-
tively (Figure 1). The patients with CAO response 
had significantly longer median OS (8.3 vs. 2.4 
months; p< 0.001) than the non-responders (Figure 
2). For the 11 patients who experienced re-CAO 
had 7.4 and 5.2 months median OS and CAO-free 
survival times, respectively. The median (8.3 vs. 
6.4 months; p= 0.014) and 1-year (26.9 vs. 10.9; 
p< 0.001) OS rates were prominently higher in 
patients receiving BED10 doses ≥39 Gy than the 
lower dose counterparts (Figure 2).
In correlation analysis by Spearman test revealed 
that the smaller tumor size (<5.3 vs. ≥5.3 cm; p= 
0.007) defined by ROC analysis, higher BED10 
dose (≥39 vs. 39 Gy; p< 0.001) and SCLC histolo-
gy (SCLC vs. NSCLC; p= 0.002) were determined 
to be the factors to associate with better CAO re-
sponse rates (Table 2). Univariate analysis assess-
ing the OS outcomes indicated that smaller tm size 
(< 5.3 cm; p= 0.04), higher EBRT dose (BED10 
≥39 Gy; p<0.001) and CAO response (present; 
p<0.001) were the factors to associate with signifi-
cantly superior median OS times (Table 3). How-
ever, multivariate analysis including only these 
Figure 2. (A) Overall survival according to the central airway obstruction status (CAO) (B) Overall survival according to the biologically 
equivalent dose-10 Gy (BED10)
Figure 1. Overall survival in all patients
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three factors demonstrated that the tumor size lost 
its significant association with OS outcomes leav-
ing the higher EBRT dose and presence of CAO 
response as the associators of longer OS (Figure 2).
DISCUSSION
The results of this present retrospective analysis 
in 72 MLC patients with CAO demonstrated that 
the EBRT efficiently palliated the CAO in 80.6% 
patients for a relatively durable time period (8.1 
months) compared to their short life span (8.3 
months) with only 19.0% CAO recurrences in the 
responders. Additional analysis revealed a signifi-
cant and independent association with better CAO 
response and longer survival in patients with SCLC 
histology and EBRT dose of BED10 ≥39 Gy. Pre-
sent results also showed that the smaller tumor 
size, SCLC histology, and BED10 ≥39 Gy were 
associated with higher CAO response rate, while 
longer survival was appeared to relate to presence 
of CAO response and BED10 ≥39 Gy EBRT dose, 
respectively.
Progressive local/regional tumor growth in MLC 
patients may lead to significant suffering from 
dyspnea, hemoptysis, and cough either of which 
may mandate urgent palliative interventions such 
as stent placement, ELA, and/or PDT.13,14 Obvi-
ously, these invasive treatment modalities are sat-
isfactorily effective in terms of providing rapid 
palliation in patients with CAO. However, to be 
applicable, first the tumor should allow the instal-
lation of the stent which may be quite difficult for 
endobronchial tumors obstructing the lumen near 
totally. Moreover, stent migration and/or obstruc-
tion are additional potential problems to be over-
come that may either limit their frequent usage or 
may indicate use of further palliative interventions. 
Similarly, EBB is another invasive technique with 
favorable palliation outcomes for CAO. However, 
great caution is needed for interpretation of the 
EBB studies as most eligible patients had intra-
bronchial small tumors without extrinsic compo-
nents. Alike with the aforementioned techniques 
EBB also suffers from a variety of notable compli-
cations including the esophageal-bronchial fistula, 
Table 2. Outcomes of Spearmen analysis for determinants of CAO response 
Characteristic Patients Response Rate Correlation Coefficient p 
 N (%) (%) (Rho-value)
Gender
   Male 52 (72.2) 80.7 -0.009 0.94
   Female 20 (27.8) 80.0 
ECOG
   0-1 36 (50.0) 77.0 0.033 0.78
   2 18 (25.0) 86.6
   3 18 (25.0) 81.3 
Tumor histology
   SCLC 53 (74.0) 89.5 0.135 0.002
   NSCLC 19 (26.0) 77.3 
Tumor size 
   < 5.3 cm  42 (58.3) 92.8 -0.355 0.007
   ≥ 5.3 cm 30 (41.7) 63.3 
BED10 (Gy)
   ≥ 39 Gy   20 (27.7) 90.3 0.400 <0.001
   < 39 Gy  52 (72.3) 55.0 
ECOG: eastern cooperative oncology group; SCLC: small-cell lung carcinoma; NSCLC: non-small cell lung carcinoma; 
BED: biologically equivalent dose; Gy: gray; 
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bronchial wall necrosis, and/or massive hemopty-
sis.8,15-18 Considering these facts, the noninvasive 
EBRT with its minimal toxicity profile may be a 
rational treatment choice in these highly fragile pa-
tients with tumors of any size independent of their 
relation with the bronchial lumen. 
One important finding of the present study was the 
excellent response rate of CAO to EBRT (80.6%) 
with relatively long CAO-free duration (8.1 
months) compared to the median OS of 8.3 months 
achieved in the responder patients. This observa-
tion clearly underlies the long lasting efficacy of 
EBRT in management of CAO. Considering the ef-
ficacy of EBRT in management of CAO, in a study 
by Lee et al. including 95 patients who were treated 
with 8 to 45 Gy (1 to 15 fractions) EBRT due to ob-
structive lung masses of NSCLC (n= 59) or SCLC 
(n= 36) were analyzed.19 The reported 79% CAO 
improvement with EBRT by Lee et al. is almost 
identical to our 80.6% response rate noted here. 
The present results are additionally confirmed by 
the reported 65-77% CAO improvement rate noted 
in the large Fairchild meta-analysis that included 
13 randomized studies and 3473 patients.20 Apart 
from this finding, we additionally demonstrated 
that even in the 11 patients (19%) who experienced 
re-obstruction after EBRT had a CAO-free interval 
of 5.2 months, corresponding to the 70% of cal-
culated remaining life span (7.4 months) in these 
patients. This additional observation may serve im-
portant considering the detrimental effects of CAO 
on patients’ quality of life and its appreciable im-
provement with EBRT. 
In spite of the well-recognized differential efficacy 
of EBRT on local tumor control in non-metastatic 
SCLC  and NSCLC patients21,22, to our best knowl-
edge, the tumor histology (NSCLC vs. SCLC) re-
lated CAO-response differences have been rarely 
addressed.19 For instance, in their aforementioned 
study Lee et al. could not demonstrate any differ-
ence between the CAO responses of NSCLC and 
SCLC patients (78.0% vs. 80.6%; p= 0.76) after 
Table 3. Results of univariate and multivariate analysis
Characteristic Patients Median Survival Univariate Multivariate
 N (%) (months) p-value p-value
Gender
   Male 52 (72.2) 7.4 0.13 –
   Female 20 (27.8) 9.4 
ECOG
   0-1 36 (50) 8.0 0.48 –
   2 18 (25) 7.6
   3 18 (25) 6.7 
Histology
   NSCLC 53 (74) 7.3 0.69 –
   SCLC 19 (26) 8.6 
Tumor size
   < 5.3 cm 42 (58.3) 8.3 0.04 0.37
   ≥ 5.3 cm 30 (41.7) 6.8  
BED10 (Gy)
   < 39 Gy 20 (27.7) 5.8 <0.001 0.008 
   ≥ 39 Gy 52 (72.3) 8.8 
CAO response
   Present 58 (80.5) 8.3 <0.001 <0.001
   Absent 14 (19.5) 2.4 
ECOG, eastern cooperative oncology group; Gy, gray; NSCLC, non-small cell lung carcinoma; SCLC, small-cell lung carcinoma; 
EBRT, external beam radiotherapy CAO, central airway obstruction; BED, biologically equivalent dose
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EBRT.19 In this respect our results are in stark 
contrast with Lee’s outcomes as SCLC patients 
appeared to demonstrate better CAO response to 
EBRT (89.5% vs. 77.3%; p= 0.002). Although it is 
difficult to assign this distinction to exact causes, 
yet it is reasonable to anticipate that the striking 
higher radiosensitivity of SCLC to RT than NSCLC 
may have played the major role on this difference.23 
This anticipation is supported by the RT doses uti-
lized in the landmark SCLC and NSCLC studies 
for non-metastatic LC patients [24-26], which is 45 
Gy for SCLC [26] and 60-66 Gy for NSCLC.24,25, 
respectively. Similarly, align with the related litera-
ture the faster maximum CAO-response observed 
here in SCLC patients than their NSCLC counter-
parts (5 vs. 28 days; p= 0.02) is also highly prob-
able to associate with the higher relative radiosen-
sitivity of the SCLC.22
In addition to better symptom improvement, high 
dose RT rather than the conventional palliative 
dose schedules may also prove survival benefit in 
patients presenting with CAO.19,20,27 In line with 
this evident dose-response relationship [20], our 
analysis demonstrated that both the actual CAO 
resolution- (90.3 vs. 55%; p< 0.01) and median- 
(8.3 vs. 6.4 months; P=0.014) and 1-year (26.9 vs. 
10.9%, p< 0.001) OS rates were significantly su-
perior with BED10 doses ≥39 Gy than the lower 
dose counterparts. This observation is strength-
ened with a recent study by Tanaka et al.27 and a 
relatively older meta-analysis by Fairchild et al.20 
In both analyses the authors reported a dose ben-
efit of EBRT was also supported by and a study of 
which addressed to 35 Gy10 as a threshold value 
for prolonged survival (27% vs. 22% at 1-year; 
p= 0.002) and favorable symptom control, respec-
tively. Therefore, altogether these results suggest 
the use of total dose and fractionation achieving for 
better results. 
 In addition to the tumor histology and EBRT dose, 
the tumor size is another suggested factor to alter 
CAO response rates after both EBB and EBRT.2,19,28 
Based on the available literature, it may be rational 
to propose that CAO caused by smaller tumors 
may response to a prescribed EBRT dose than 
larger ones, as it is evident from LC literature.29 
In this respect, tumor size of <6 cm was reported 
to associate with better CAO-free19 and local con-
trol rates [30]. Similarly in our present study, the 
ROC analysis identified that patients with <5.3 cm 
tumor size as the cut off for better RT response 
(92.8 vs. 63.3%; p= 0.007) and median CAO-free 
interval (8.3 vs. 5.7 months; p= 0.012), this could 
not translate into a significant covariate affect-
ing the outcomes in the multivariate analysis (p= 
0.41). Therefore, the outcomes of Tanaka’s study 
and the one presented here suggest a potential role 
for tumor size in prediction of CAO-response af-
ter EBRT, which deserve to be addressed in larger 
studies to conclude in a more reliable manner.
The present study has several drawbacks. First, 
as common to any single institutional small ret-
rospective study, unpredictable biases may have 
influenced our results. Second, absence of the 
patient-reported objective questionnaire forms 
and functional examinations including respiratory 
function tests or bronchoscopic evaluations limit 
our ability to conclude more reliably. Instead, we 
utilized serial chest X-rays, patients’ self-assess-
ments, and physician in charge’s judgement based 
on the physical examinations which are prone to 
biasing effects as they are more or less subjective 
evaluation tools. However, although we recognize 
the handicaps of subjective assessments, it should 
be remembered that use of more objective tools 
such as the respiratory function tests or CT scan-
ning may be extremely difficult or even impossi-
ble in at least some patients with severe dyspnea. 
Fourth, use of different EBRT dose fractionation 
schedules in discretion of the physician in charge 
by considering the patients’ general health status 
may have favored one group over the other, partic-
ularly the high dose group. In this respect, the dose 
response relationship in different performance sta-
tus levels and its translation to survival outcomes 
in such patients deserves to be addressed in fu-
ture studies with larger cohorts. And fifth, use of 
various chemotherapeutics and/or targeted agents 
in some patients may have potentially altered the 
outcomes reported here. Therefore, respecting 
these limitations, we believe that our results should 
better be interpreted with caution considering the 
above mentioned factors.  
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CONCLUSION
The outcomes of current retrospective analysis 
demonstrated efficacy of the EBRT in palliation of 
the NSCLC or SCLC originated CAO for almost 
the rest of their remaining life span in responders, 
with only 19.0% CAO recurrences. Additionally 
we identified the higher EBRT dose (BED10 ≥39 
Gy), smaller tumor size (<5.3 cm) and SCLC his-
tology as the factors to associate with better CAO 
response after the noninvasive EBRT. 
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